Abeona Therapeutics Gross Profit 2006-2021 | ABEO

Abeona Therapeutics gross profit from 2006 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Abeona Therapeutics Annual Gross Profit
(Millions of US $)
2020 $10
2019 $
2018 $3
2017 $1
2016 $1
2015 $1
2014 $1
2013 $2
2012 $4
2011 $2
2010 $0
2009 $0
2008 $0
2007 $0
2006 $
2005 $
Abeona Therapeutics Quarterly Gross Profit
(Millions of US $)
2021-09-30
2021-06-30
2021-03-31
2020-12-31 $3
2020-09-30 $7
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31 $0
2018-09-30 $2
2018-06-30 $0
2018-03-31 $1
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $2
2011-12-31 $1
2011-09-30 $1
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
2008-12-31 $0
2008-09-30 $0
2008-06-30 $0
2008-03-31 $0
2007-12-31 $0
2007-09-30 $0
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
2005-12-31
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.026B $0.010B
Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00